Literature DB >> 28504565

Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.

Gregory G Schwartz1, Rana Fayyad2, Michael Szarek3, David DeMicco2, Anders G Olsson4.   

Abstract

Background Early, intensive statin treatment is the standard of care after acute coronary syndrome (ACS). However, the benefit of this approach to prevent major adverse cardiovascular events has been demonstrated in only one randomised, placebo controlled trial. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial demonstrated that atorvastatin 80 mg daily, compared with placebo, reduced time to first occurrence of death, non-fatal myocardial infarction, resuscitated cardiac arrest, or hospitalisation for unstable angina (stroke not included) during the 16 week period following ACS. However, there were no significant effects on individual components of the composite endpoint except unstable angina. This led some to question whether early, intensive statin treatment reduces 'hard' events after ACS. Aim The burden of coronary heart disease after ACS, and therefore the efficacy of its treatment, depends not only on the occurrence of one ischaemic event, but rather on cumulative events experienced by patients. Accordingly, we conducted a post-hoc analysis of the MIRACL trial to examine the effect of atorvastatin on first as well as recurrent (i.e. total) hard cardiovascular events after ACS (death, myocardial infarction, stroke, and resuscitated cardiac arrest). Methods and Results In the 3086 patients who comprised the MIRACL trial, atorvastatin 80 mg did not reduce time to first hard event compared with placebo (hazard ratio 0.89, 95% confidence interval 0.72-1.10, P = 0.27). However, atorvastatin significantly reduced total hard events (hazard ratio 0.80, 95% confidence interval 0.66-0.97, P = 0.03). To prevent one hard event during the 16 weeks following ACS, only 11 patient-years of treatment with atorvastatin were required. Conclusion Early, intensive treatment with atorvastatin is an efficient intervention to reduce hard cardiovascular events after ACS.

Entities:  

Keywords:  Statin; acute coronary syndrome

Mesh:

Substances:

Year:  2017        PMID: 28504565     DOI: 10.1177/2047487317708677

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  7 in total

1.  Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?

Authors:  Ingrid Škorňová; Matej Samoš; Tomáš Bolek; Lucia Stančiaková; Ľubica Vádelová; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň
Journal:  Pharmacol Res Perspect       Date:  2021-05

2.  Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles.

Authors:  Yuzhou Xue; Jian Shen; Weifeng Hong; Wei Zhou; Zhenxian Xiang; Yuansong Zhu; Chuiguo Huang; Suxin Luo
Journal:  Lipids Health Dis       Date:  2021-05-06       Impact factor: 3.876

3.  Intensive statin treatment ameliorate the Th17/Treg functional imbalance in patients with non-ST elevation acute coronary syndrome underwent percutaneous coronary intervention.

Authors:  Xiaojing Ma; Shilei Liu; Teng Li; Haitao Yuan
Journal:  Clin Cardiol       Date:  2019-12-24       Impact factor: 2.882

4.  The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.

Authors:  Onur Argan; Kübra Çıkrıkçı; Aybike Baltacı; Nahit Gencer
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Comparison of two diagnostic protocols in the management of possible cardiac chest pain: One follow-up study in Iran.

Authors:  Kamran Heidari; Mahbube Asghari Arani; Mehdi Sheibani; John W Pickering; Arezoo Chouhdari
Journal:  Caspian J Intern Med       Date:  2021-03

6.  Modulation of Ion Channels in the Superior Cervical Ganglion Neurons by Myocardial Ischemia and Fluvastatin Treatment.

Authors:  Lijun Cheng; Xinghua Wang; Tong Liu; Gary Tse; Huaying Fu; Guangping Li
Journal:  Front Physiol       Date:  2018-09-10       Impact factor: 4.566

Review 7.  The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme.

Authors:  Riccardo Sarzani; Massimiliano Allevi; Federico Giulietti; Chiara Di Pentima; Serena Re; Piero Giordano; Francesco Spannella
Journal:  J Clin Med       Date:  2021-12-15       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.